December 16, 2015

Critical Outcome Technologies Reports Second Quarter Financial and Operating Results

December 10, 2015

COTI-2 Moves Into Human Testing

December 2, 2015

Critical Outcome Technologies Pursues Orphan Drug Designation for COTI-2 Intended to Treat Li-Fraumeni Syndrome

October 19, 2015

Critical Outcome Technologies Awards Stock Options

October 16, 2015

Critical Outcome Technologies Provides Update on Recent Milestone Achievements and Future Strategic Objectives at Annual General Meeting

September 29, 2015

Critical Outcome Technologies Updates First Quarter Financial and Operating Results

September 29, 2015

Critical Outcome Technologies Reports First Quarter Financial and Operating Results

September 1, 2015

Critical Outcome Technologies Provides Clarification Regarding Investor Relations Engagement

September 1, 2015

Critical Outcome Technologies Strengthens Its Investor Relations Capabilities

August 28, 2015

Critical Outcome Technologies Reports Year‐End Financial And Operating Results

August 4, 2015

Critical Outcome Technologies Completes Private Placement Supporting Its Phase 1 Clinical Trial for p53-Dependent Gynecological Cancers

June 30, 2015

Critical Outcome Technologies Closes Financing

May 26, 2015

FDA Grants IND to Critical Outcome Technologies for COTI-2, the Company’s Activator of Mutant p53 Protein

May 14, 2015

Critical Outcome Technologies Strengthens Its Board

May 11, 2015

Critical Outcome Technologies Adds First European Patent to Growing Intellectual Property Protection for COTI-2

April 27, 2015

Critical Outcome Technologies Files Investigational New Drug Application with the FDA for COTI-2

April 15, 2015

Critical Outcome Technologies Receives First U.S. Patent for Next Generation HIV Treatment

April 2, 2015

Critical Outcome Technologies Inc. Strengthens Its Investor Relations Outreach

March 23, 2015

Critical Outcome Technologies Establishes Advisory Board for the Clinical Development of COTI-2

March 20, 2015

Critical Outcome Technologies Reports Fiscal 2015 Third Quarter Results

March 2, 2015

Critical Outcome Provides Update on COTI-2 IND Filing

February 18, 2015

Critical Outcome Technologies Closes Private Placement

January 20, 2015

Critical Outcome Technologies Planning Phase 1 Clinical Trial Of COTI-2 in Recurrent Head and Neck Cancers